Key result
A novel point-of-care testing device for heart failure management had a median commercial headroom of €1.64 (IQR €0.05-€3.16) per daily measurement at a €10,000 per life-year willingness-to-pay threshold.
Why the study?
Early estimates of the commercial headroom available to a new medical device can assist producers in making appropriate product investment decisions, but methods to capture this probabilistically were needed.
Effect estimate: Median €1.64 (95% CI IQR €0.05-€3.16)
Probabilistic headroom estimation may guide early device investment in heart failure; leaves open real-world validation and adoption impact.
OBJECTIVES: Early estimates of the commercial headroom available to a new medical device can assist producers of health technology in making appropriate product investment decisions. The purpose of this study was to illustrate how this quantity can be captured probabilistically by combining probability elicitation with early health economic modeling. The technology considered was a novel point-of-care testing device in heart failure disease management. METHODS: First, we developed a continuous-time Markov model to represent the patients' disease progression under the current care setting. Next, we identified the model parameters that are likely to change after the introduction of the new device and interviewed three cardiologists to capture the probability distributions of these parameters. Finally, we obtained the probability distribution of the commercial headroom available per measurement by propagating the uncertainty in the model inputs to uncertainty in modeled outcomes. RESULTS: For a willingness-to-pay value of €10,000 per life-year, the median headroom available per measurement was €1.64 (interquartile range €0.05-€3.16) when the measurement frequency was assumed to be daily. In the subsequently conducted sensitivity analysis, this median value increased to a maximum of €57.70 for different combinations of the willingness-to-pay threshold and the measurement frequency. CONCLUSIONS: Probability elicitation can successfully be combined with early health economic modeling to obtain the probability distribution of the headroom available to a new medical technology. Subsequently feeding this distribution into a product investment evaluation method enables stakeholders to make more informed decisions regarding to which markets a currently available product prototype should be targeted.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2013) studied Heart failure (n=3). Novel point-of-care testing device vs. Current care setting was evaluated on Commercial headroom available per measurement (Median €1.64, 95% CI IQR €0.05-€3.16). A novel point-of-care testing device for heart failure management had a median commercial headroom of €1.64 (IQR €0.05-€3.16) per daily measurement at a €10,000 per life-year willingness-to-pay threshold.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: